论文部分内容阅读
目的探讨曲美他嗪对不稳定型心绞痛(UAP)并糖尿病患者血管内皮功能和心功能的影响。方法选取UAP并糖尿病患者80例,随机分为治疗组(40例)和对照组(40例),对照组给予常规治疗,治疗组在对照组治疗的基础上加用盐酸曲美他嗪,两组均治疗6个月。治疗前后检测血管内皮功能[血浆内皮素(ET)、一氧化氮(NO)、肱动脉血流介导内皮依赖性血管舒张功能(FMD)]和心功能指标[心输出量(CO)、心室舒张早期二尖瓣血流峰值和舒张晚期二尖瓣血流峰值之比(E/A)、左室射血分数(LVEF)]的变化。结果治疗后治疗组ET、NO、FMD、CO、E/A、LVEF分别为(44.68±5.80)ng/L、(82.10±10.42)μmol/L、11.09%±0.91%、(4.93±0.91)L/min、0.84±0.13、52.4%±4.5%,各指标的改善均优于对照组[分别为(49.70±6.43)ng/L、(64.25±9.44)μmol/L、10.16%±0.85%、(4.51±0.93)L/min、0.96±0.12、50.1%±4.9%],差异均有统计学意义(P<0.05或P<0.01),治疗组未发生与曲美他嗪相关的不良反应。结论曲美他嗪具有改善血管内皮功能和心功能的作用,无明显的不良反应。
Objective To investigate the effect of trimetazidine on vascular endothelial function and cardiac function in patients with unstable angina pectoris (UAP) and diabetes mellitus. Methods 80 patients with UAP and diabetes mellitus were randomly divided into treatment group (40 cases) and control group (40 cases). The control group was given routine treatment. The treatment group was given Trimetazidine Hydrochloride on the basis of the control group. Group were treated for 6 months. The levels of endothelin (ET, NO, bradycardia-mediated endothelium-dependent vasodilatation (FMD)] and cardiac function [cardiac output (CO) Early diastolic mitral flow peak and late diastolic mitral flow peak ratio (E / A), left ventricular ejection fraction (LVEF)] changes. Results The levels of ET, NO, FMD, CO, E / A and LVEF were (44.68 ± 5.80) ng / L, (82.10 ± 10.42) μmol / L and 11.09% ± 0.91%, (4.93 ± 0.91) L /min, 0.84 ± 0.13 and 52.4% ±4.5% respectively, the improvement of each index was better than that of the control group [(49.70 ± 6.43) ng / L, (64.25 ± 9.44) μmol / L, 10.16% ± 0.85% 4.51 ± 0.93) L / min, 0.96 ± 0.12 and 50.1% ± 4.9%, respectively. The differences were statistically significant (P <0.05 or P <0.01). No trimetazidine-related adverse reactions were observed in the treatment group. Conclusion Trimetazidine has the effect of improving vascular endothelial function and cardiac function without obvious adverse reactions.